Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on the research and development of cannabinoid-based therapies for disorders of the central nervous system. The company operates within the biopharmaceutical and cannabinoid therapeutics industries, with an emphasis on developing novel drug candidates that address unmet medical needs through modulation of the endocannabinoid system.
The company’s primary value is derived from its pipeline of proprietary drug candidates and its controlling interest in Therapix Biosciences Ltd., which conducts much of the company’s clinical and preclinical development activity. SciSparc targets patient populations in neurology and psychiatry, including conditions such as Tourette syndrome, autism spectrum disorder, Alzheimer’s disease, and chronic pain. The company was founded in Israel and has evolved from an early-stage cannabinoid research platform into a publicly traded clinical development company listed on Nasdaq under the ticker SPRC.
Business Operations
SciSparc generates no material commercial revenue and operates as a development-stage enterprise. Its business activities are primarily centered on drug discovery, clinical trials, regulatory strategy, and intellectual property management. Core development programs include cannabinoid-based formulations such as SCI-110, SCI-160, and SCI-210, which are designed to leverage synthetic or purified cannabinoids for specific neurological and neuropsychiatric indications.
Operationally, the company conducts research and development largely through Therapix Biosciences Ltd., its principal operating subsidiary. SciSparc also maintains equity interests in other cannabinoid-focused companies, which are managed as strategic investments rather than fully consolidated operating businesses. Clinical trials and research collaborations are conducted internationally, while corporate, financial, and regulatory oversight is retained at the parent-company level.
Strategic Position & Investments
SciSparc’s strategy is centered on building a diversified cannabinoid-focused therapeutic pipeline while maintaining capital flexibility through strategic equity investments. The company has pursued growth through acquisitions and equity stakes, most notably its controlling ownership of Therapix Biosciences Ltd. and investments in publicly traded cannabinoid and psychedelic medicine companies, including Clearmind Medicine Inc., subject to market and regulatory conditions.
The company positions itself as a specialized platform for cannabinoid drug development rather than a consumer cannabis business. Its strategic direction emphasizes advancing late preclinical and early clinical programs, pursuing regulatory pathways in the United States and other major markets, and selectively monetizing assets through partnerships or licensing arrangements. Data regarding the long-term commercial strategy remains limited based on available public disclosures.
Geographic Footprint
SciSparc is headquartered in Israel, where it maintains its principal executive offices and strategic oversight functions. Research and development activities are primarily conducted through Israeli subsidiaries, with additional clinical trial operations extending into North America and Europe, depending on study design and regulatory requirements.
As a Nasdaq-listed company, SciSparc maintains a capital markets presence in the United States, which supports investor relations, financing activities, and regulatory reporting. While the company does not currently operate commercial sales infrastructure, its clinical and regulatory efforts are designed to support potential future market entry in multiple global regions.
Leadership & Governance
SciSparc is led by an executive team with experience in pharmaceuticals, biotechnology, and capital markets. The leadership emphasizes disciplined capital allocation, focus on clinical milestones, and leveraging the scientific potential of cannabinoid-based compounds. Public disclosures describe a strategy centered on advancing scientifically differentiated assets while managing development risk.
Key executives include:
- Oz Adler – Chief Executive Officer
- Itzik Cohen – Chairman of the Board
- Adi Nahmani – Chief Financial Officer
- Dr. David Gurwitz – Scientific Advisor
Information regarding founder attribution and broader governance practices beyond board composition is limited; data inconclusive based on available public sources.